Anti-PD-1 therapy enhanced T cells infiltration in TSC2-deficient tumors, inhibited tumor growth by 62% (p < 0.0001) [61] and improved the survival rates of LAM mice (p < 0.0001) [62]. This evidence concerns the gene RPL17 and neoplasm.